Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a, Multicenter, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of NBI-1117567 in Participants With Mild to Moderate Alzheimer's Disease on Stable Treatment With an Acetylcholinesterase Inhibitor

NCT07832383 is registered in ClinicalTrials.gov with Neurocrine Biosciences as lead sponsor.

NCT NCT07832383
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07832383 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a, Multicenter, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of NBI-1117567 in Participants With Mild to Moderate Alzheimer's Disease on Stable Treatment With an Acetylcholinesterase Inhibitor
Lead sponsor
Neurocrine Biosciences
Phase
Phase 2
Overall status
Not yet recruiting
Start date
October 31, 2026
Completion date
June 30, 2028
Enrollment
135 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease